###### Significance Statement

This is the first study, to our knowledge, in adolescents showing that improvement in depression severity after antidepressant treatment is associated with restored cortical inhibition, as indexed by short-interval cortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS). These findings provide important preliminary data that will inform future studies investigating the neurobiology of adolescent depression and enable the development of better diagnostic methods and individualized, biomarker-guided therapeutic approaches in this population.

Introduction {#s1}
============

Major depressive disorder (MDD) is one of the most common psychiatric illnesses for adolescents, with estimated 1-year and lifetime prevalence rates of 8% and 11%, respectively. Depression in youth is associated with increased psychiatric comorbidities, suicide risk, and considerable negative impact on quality of life and morbidity ([@CIT0007]; [@CIT0057]; [@CIT0005]). Despite available treatments, only approximately 60% of patients respond to standard treatments, and remission rates are 30% to 40% ([@CIT0051]; [@CIT0010]; [@CIT0005]).

The neurobiology of depression in children and adolescents has several potential mechanisms, including aberrant neurocircuitry in the amygdala, hypothalamus, and subgenual anterior cingulate cortex; genetic and epigenetic factors; and hypothalamic-pituitary-adrenal hyperactivity ([@CIT0075]; [@CIT0037]). Current evidence also suggests an altered excitatory-inhibitory balance of cortical networks in depression ([@CIT0045]; [@CIT0011]; [@CIT0004]). For example, studies using proton magnetic resonance spectroscopy have shown that levels of γ-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the brain, are reduced in adults and adolescents with depression ([@CIT0036]; [@CIT0026], [@CIT0027]) and that treatment with antidepressants can restore GABAergic inhibition ([@CIT0050]; [@CIT0064]; [@CIT0063]; [@CIT0053]). In addition to reduced GABAergic inhibition, elevated glutamate levels ([@CIT0066]) and excitatory activity have also been associated with depression. Indeed, glutamatergic antagonism with ketamine has been associated with antidepressant effects ([@CIT0023]). Despite these promising results in understanding the potential role of altered excitatory-inhibitory balance in the pathophysiology of depression, its implications in children and adolescents require further investigation because of the incomplete maturation of the young brain and developmental shifts in excitatory-inhibitory balance in children and adolescents ([@CIT0014]; [@CIT0032]).

Single- and paired-pulse transcranial magnetic stimulation (TMS) offers a noninvasive way to measure inhibitory and excitatory activity associated with GABAergic and glutamatergic pathways, which are impaired in depression ([@CIT0045]; [@CIT0011]; [@CIT0062]). When coupled with electromyography, TMS can quantify the stimulus effect in the motor cortex by measuring motor-evoked potentials (MEPs). TMS-induced effects on MEPs are measured with various paradigms, including intracortical inhibition (ICI), interhemispheric inhibition, cortical silent period (CSP), intracortical facilitation (ICF), and motor threshold ([@CIT0003]). ICF is a measure of cortical excitability ([@CIT0043]; [@CIT0033]; [@CIT0079]) and is most likely mediated through *N*-methyl-[d]{.smallcaps}-aspartate glutamatergic receptor activity ([@CIT0047]; [@CIT0078]; [@CIT0067], [@CIT0068]), whereas ICI and CSP ([@CIT0017], [@CIT0018]; [@CIT0008]; [@CIT0069]; [@CIT0070]) are measures of cortical inhibition and are mediated through GABAergic function ([@CIT0076], [@CIT0077]). Depending on the duration of the interstimulus interval (ISI) and the intensity of the conditioning stimulus, ICI can be further categorized as SICI (ISIs of 2--4 milliseconds) ([@CIT0033]; [@CIT0079]; [@CIT0019]; [@CIT0024]) and long-interval intracortical inhibition (LICI; ISIs of 100--200 milliseconds) ([@CIT0072]; [@CIT0039]; [@CIT0054]; [@CIT0009]; [@CIT0021]), which are thought to reflect GABA~A~ and GABA~B~ receptor functioning, respectively ([@CIT0034]; [@CIT0073]; [@CIT0020], [@CIT0021]; [@CIT0038]; [@CIT0035]; [@CIT0058]; [@CIT0052]).

A meta-analysis of TMS studies ([@CIT0062]) showed impaired CSP (a measure of GABA~B~ activity) and SICI (a measure of GABA~A~ activity) in adults with MDD compared with healthy controls. Other studies of adults treated for MDD found a relationship between the restoration of GABAergic activity measured by TMS and antidepressant treatment ([@CIT0050]; [@CIT0064]; [@CIT0063]; [@CIT0053]). The few studies that investigated TMS correlates of depression in children and adolescents have reported mixed results. Our group previously reported elevated ICF in medication-naïve children and adolescents with depression ([@CIT0012]), an association between pretreatment LICI deficits and poor treatment response to fluoxetine ([@CIT0013]), and an inverse relationship between depression severity and CSP duration ([@CIT0046]). However, the adolescent TMS literature to date has consisted of cross-sectional studies.

In this study, we aimed to investigate TMS correlates of longitudinal treatment outcomes in children and adolescents with MDD. We assessed TMS measures of cortical inhibition and excitability in (1) a sample of adolescents with depression who received antidepressant pharmacotherapy, and (2) a healthy control comparator group. Among adolescents with MDD who were receiving antidepressants, we further explored pretreatment and posttreatment changes in TMS measures of cortical inhibition and excitability. On the basis of prior evidence in adults and our previous work, we hypothesized that adolescents with depression would have impaired cortical inhibition and that the improvement in depression severity would be associated with enhanced cortical inhibition.

Materials and Methods {#s2}
=====================

All study procedures were approved by the institutional review boards of Mayo Clinic and University of Texas Southwestern Medical Center. Informed consent was obtained from the participants' legal guardians or parents, and assent was obtained from adolescent participants.

Participants {#s3}
------------

The sample consisted of treatment-seeking participants with MDD (age 13--17 years ) who were a subset of a sample of adolescents recruited from clinical practices as part of a larger study (ClinicalTrials.gov identifier: NCT02307617). Patients were recruited at Mayo Clinic (Rochester, MN). Healthy controls (age 9--17 years) were recruited as part of a previous trial with identical TMS methodology ([@CIT0012]); their data were included in the current analysis. Healthy participants were recruited at UT Southwestern Medical Center (Dallas, Texas).

Inclusion criteria for depressed participants were as follows: (1) MDD that was diagnosed by a clinical and research interview with the Schedule for Affective Disorders and Schizophrenia for School Age Children--Present and Lifetime Version (K-SADS-PL) ([@CIT0041]); (2) a minimum score of 40 on the Children's Depression Rating Scale, Revised (CDRS-R) ([@CIT0060]; [@CIT0061]) and a score of 4 or more on the Clinical Global Impression--Severity (CGI-S) ([@CIT0031]) consistent with at least moderate depressive symptom severity; and (3) no use of stimulant or benzodiazepine medications on the day of TMS assessments. A board-certified child and adolescent psychiatrist (P.E.C.) completed all clinical interviews, K-SADS-PL interviews, and clinical rating scales.

Potential patients and controls were ineligible for the study if they had a contraindication to TMS, as assessed by the TMS Adult Safety Screen ([@CIT0042]). Contraindications were a history of unprovoked seizures, seizure disorder, history of febrile seizures, family history of epilepsy, prior neurosurgery, or brain tumor. Potential controls were excluded if they had a personal history of psychiatric treatment or psychotropic medications, or a family history (first- or second-degree relatives) of psychiatric illness.

Study Overview and Clinical Measures {#s4}
------------------------------------

The CDRS-R, K-SADS-PL, CGI-S, Edinburgh Handedness Inventory ([@CIT0056]), and Columbia Suicide Severity Rating Scale ([@CIT0059]) were administered at baseline. Single-pulse and paired-pulse TMS measures were obtained from each participant. Depressed participants receiving pharmacotherapy were asked to return for a follow-up visit in about 8 weeks. At follow-up, they again underwent assessment with single- and paired-pulse TMS and clinical measures (CDRS-R, CGI-S, Clinical Global Impression--Improvement, and Columbia Suicide Severity Rating Scale).

The CDRS-R was used to measure baseline and follow-up depression severity. The CDRS-R is a clinician-rated 17-item scale that incorporates scores from a parent and the adolescent to determine a composite score. All study participants completed the CDRS-R. For the depressed patients who returned for follow-up, the difference between baseline and follow-up scores was calculated to quantify change in depressive symptoms that occurred during the treatment period.

TMS {#s5}
---

Magnetic pulses were generated by Magstim 200 magnetic stimulators connected via a BiStim Module (Magstim Co. Ltd). TMS measures were obtained from the left primary motor cortex, which was stimulated with a 70-mm figure-of-8 electromagnetic coil placed tangentially over the scalp. Participants remained seated throughout the procedure and wore earplugs. MEPs were recorded via surface electromyography of the contralateral abductor pollicis brevis (APB). The optimal scalp location for APB stimulation was determined according to a previously published method ([@CIT0015]). The APB location was found by manual movement of the TMS coil while administering single pulses, followed by titration of the magnetic pulse intensity to determine the motor threshold. This was conducted in as few pulses as possible (maximum of 144, typically fewer than 72), with a rest period of 5 minutes or longer to reduce the impact of these preliminary single pulses on subsequent measures of excitability and inhibition.

Single-pulse paradigms included determination of the resting motor threshold (RMT), defined as the pulse intensity to elicit a minimum 50-μV peak-to-peak MEP response on electromyography in 5 of 10 trials. The CSP was obtained via the delivery of a single TMS pulse at 140% of RMT while participants contracted their contralateral APB at 20% of maximum contraction strength, as measured by a hand-held dynamometer. CSP duration was measured from the TMS pulse to the spontaneous resumption of motor activity on electromyography. Mean CSP duration was calculated from 10 trials.

For the paired-pulse SICI and ICF paradigms, the conditioning stimulus was set to 80% of each participant's RMT, while the subsequent test stimulus was delivered at the intensity that resulted in a peak-to-peak MEP amplitude of 1 mV. SICI was tested using ISIs of 2 or 4 milliseconds, and ICF was tested using ISIs of 10, 15, or 20 milliseconds. LICI was tested using 2 identical suprathreshold stimuli (both calibrated to evoke 1-mV peak-to-peak amplitude MEPs) separated by ISIs of 100, 150, or 200 milliseconds. SICI, LICI, and ICF were recorded as the ratio of the conditioned MEP amplitude (elicited by the test \[second\] stimulus) to the mean unconditioned MEP amplitude. A conditioned/unconditioned MEP amplitude ratio \<1.0 indicated net inhibition, whereas a ratio \>1.0 indicated net facilitation. Twelve trials at each ISI were performed (10 trials for LICI) and averaged.

Statistical Analysis {#s6}
--------------------

Statistical analyses were performed with Stata/MP 14.1 (StataCorp, LLC). Continuous variables were described with means and standard deviations. Categorical variables were described with frequencies and percentages. Demographic and clinical variables were compared with χ^2^ tests for categorical variables and *t* tests for continuous variables.

Healthy participants and depressed participants were compared by using a robust regression model for each TMS measure in which the TMS measure was the dependent variable and "group" was the independent variable, with age and sex included as covariates. In all of our regression models, we used a "robust regression" analysis (Stata/MP 14.1, StataCorp, LLC) that allows weighted analysis for outliers based on the residuals. Posthoc correction for multiple comparisons was completed by the Bonferroni method for a total of 9 comparisons.

For the subgroup of depressed participants who returned for follow-up assessments after treatment with antidepressant medication, the associations between the change in depression severity (ΔCDRS-R) and the change in TMS measures between baseline and follow-up visits was tested in a robust regression model. The change in CDRS-R score was the dependent variable and the change in each TMS measure was the independent variable, with age and sex included as covariates.

Given the limited number of covariates we could add in our regression models, we also ran 2 exploratory sensitivity analyses to test the possible effects of medications on measures of cortical excitability that had significant results in the main analyses.

Results {#s7}
=======

Participant Characteristics {#s8}
---------------------------

[Table 1](#T1){ref-type="table"} shows the demographic characteristics of the participants. The depressed group consisted of 15 participants (9 female; mean \[SD\] age, 15.4 \[1.2\] years; age range, 13--17 years). The mean (SD) length of illness was 1.3 (1.8) years. The healthy control group consisted of 22 participants (11 female; mean \[SD\] age, 13.8 \[2.2\] years; age range, 9--17 years). Among the depressed participants, 11 participants were experiencing their first episode of depression, and the remaining 4 had recurrent depression (range 2--3 episodes). Two of the patients were previously treated with sertraline. Thirty-three percent of the depressed participants had co-morbid attention-deficit/hyperactivity disorder, 13% had generalized anxiety disorder, 13% had posttraumatic stress disorder, 13% had dysthymia, and 13% had substance use (cannabis, alcohol) that did not meet the threshold for a diagnosis of a substance use disorder. We noted significant baseline differences between groups for age (*t* = −2.63; *P* = .01), race/ethnicity (χ^2^ = 9.9; *P* = .02), and CDRS-R scores (*t* = −19.88; *P* \< .001).

###### 

Characteristics of Depressed Participants and Healthy Controls (N = 37)

  Characteristic                                   Healthy Controls (n = 22)   Depressed Participants (n = 15)   *P* Value^*a*^
  ------------------------------------------------ --------------------------- --------------------------------- ----------------
  Age, y                                                                                                         
   Mean (SD)                                       13.8 (2.2)                  15.4 (1.2)                        .01
   Range                                           9--17                       13--17                            
  Male sex, No. (%)                                11 (50)                     6 (40)                            .55
  Race/ethnicity, No. (%)                                                                                        .02
   White                                           8 (36)                      13 (87)                           
   Black                                           11 (50)                     1 (7)                             
   Hispanic                                        1 (5)                       0 (0)                             
   Other                                           2 (9)                       1 (7)                             
   Right handedness, No. (%)                       20 (91)                     13 (87)                           .68
  Comorbid psychiatric diagnoses, No. (%)          ---                                                           ---
   ADHD                                                                        5 (33)                            
   GAD                                                                         2 (13)                            
   PTSD                                                                        2 (13)                            
   Dysthymia                                                                   2 (13)                            
   Substance use^*b*^                                                          2 (13)                            
   Other^*c*^                                                                  3 (20)                            
  Family history of psychiatric illness, No. (%)   0 (0)                       14 (93)                           
  CDRS-R                                                                                                         \<.001
   Mean (SD)                                       19.6 (1.6)                  53.7 (7.9)                        
   Range                                           17--24                      42--66                            
  CGI-S                                            ---                                                           ---
   Mean (SD)                                                                   5.0 (0.8)                         
   Range                                                                       4--6                              
  Current mood episode duration, y                 ---                                                           ---
   Mean (SD)                                                                   1.3 (1.8)                         
   Range                                                                       0.1--7.0                          
  Previous mood episode(s), No. (%)                ---                         4 (27)                            ---
  Medications after initial assessments (n = 10)   ---                                                           ---
  Fluoxetine                                                                   8 (80)                            
  Bupropion                                                                    1 (10)                            
  Escitalopram                                                                 1 (10)                            

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CDRS-R, Children's Depression Rating Scale, Revised; CGI-S, Clinical Global Impression--Severity; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision; GAD, generalized anxiety disorder; K-SADS-PL, Schedule for Affective Disorders and Schizophrenia for School Age Children−Present and Lifetime Version; PTSD, posttraumatic stress disorder.

^*a*^ χ^2^ or *t* test.

^*b*^ Cannabis use, not meeting DSM-IV-TR diagnostic criteria for cannabis abuse or dependence on K-SADS-PL.

^*c*^ Tic disorder (n = 1), prenatal alcohol exposure (n = 1), history of concussions (n = 1).

Due to group differences in age and sex, we added these as covariates in our regression models. For race/ethnicity, given limited sample size, we did not include it as a covariate but ran secondary analyses comparing baseline TMS measures between black and white participants within the healthy group, as the majority of black participants were in this group (11 of 12). No differences were found between black and white participants on any of the TMS excitability measures (all *P* \> .05).

With regard to medication use, one of the depressed participants was taking fluoxetine at the time of the baseline visit. Four patients were being treated with stimulant medications, which were withheld on the day of TMS assessments. Of the 10 participants who later returned for follow-up assessment, 9 were started on antidepressant medications after the baseline visit, and 1 patient who was taking fluoxetine at baseline had a dose increase after baseline TMS and clinical measures were obtained. Of these 10 patients, 8 were prescribed fluoxetine (maximum daily dose, 20--60 mg), 1 started treatment with bupropion (maximum daily dose, 150 mg), and 1 started treatment with escitalopram (maximum daily dose, 10 mg).

Baseline Comparison of TMS Measures Between Groups {#s9}
--------------------------------------------------

In the healthy group, SICI data was missing for 1 patient, ICF was missing for 1, LICI was missing for 3, and CSP was missing for 4 participants. There were no missing data for the patient group. Baseline comparison of groups with robust regression controlled for age and sex showed significant differences between healthy and depressed adolescents in SICI-2 (*P* = .001, *R*^2^ = 0.30) and SICI-4 (*P* = .027, *R*^2^ = .15). There were no significant differences between the healthy control and depressed groups for other TMS measures, including CSP (*P* = .62), LICI-100 (*P* = .83), LICI-150 (*P* = .16), LICI-200 (*P* = .80), ICF-10 (*P* = .13), ICF-15 (*P* = .10), and ICF-20 (*P* = .44). When corrected for multiple comparisons, only SICI-2 remained significant (*P*~adj~ = .01), while SICI-4 was not (*P*~adj~ = .24). [Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"} show mean values of each measurement for both groups.

![Baseline transcranial magnetic stimulation (TMS) measures for depressed participants and healthy controls. Error bars represent standard error of means. (A) Comparison of short-interval intracortical inhibition (SICI), intracortical facilitation (ICF), and long-interval intracortical inhibition (LICI). Numbers (e.g., SICI-2) represent the interstimulus intervals in milliseconds. The asterisk indicates a significant group difference after Bonferroni correction for multiple comparisons (*P* = .001, *P*~adj~ = .01). (B) Comparison of cortical silent period (CSP) duration. MEP, motor-evoked potential.](pyz021f0001){#F1}

###### 

Baseline and Follow-up Transcranial Magnetic Stimulation Measures

                          Depressed Participants                      
  --------- ------------- ------------------------ ------------------ -------
  SICI                                                                
   2 ms     0.45 (0.23)   0.88 (0.39)              1.06 (0.53)        .01
   4 ms     0.69 (0.35)   0.98 (0.48)              1.15 (0.62)^*c*^   .24
  ICF                                                                 
   10 ms    1.47 (0.55)   1.66 (0.53)              1.58 (0.67)        \>.99
   15 ms    1.53 (0.71)   1.81 (0.84)              1.49 (0.51)        .87
   20 ms    1.43 (0.66)   1.71 (0.74)              1.34 (0.53)        \>.99
  LICI                                                                
   100 ms   0.20 (0.28)   0.93 (2.27)              0.31 (0.29)        \>.99
   150 ms   0.32 (0.48)   0.76 (1.30)              0.44 (0.42)        \>.99
   200 ms   1.39 (1.18)   1.29 (1.23)              0.60 (0.46)        \>.99
  CSP, s    0.18 (0.04)   0.17 (0.05)              0.16 (0.03)        \>.99

Abbreviations: CDRS-R, Children's Depression Rating Scale, Revised; CSP, cortical silent period; ICF, intracortical facilitation; LICI, long-interval intracortical inhibition; SICI, short-interval intracortical inhibition.

^*a*^ Follow-up assessment timeframe: mean \[SD\] follow-up time, 7.9 \[5.6\] weeks; range, 2--20 weeks) for a subset of depressed participants treated with antidepressant medication.

^*b*^ Comparison of healthy vs depressed participants at baseline. Bonferroni-corrected *P* values (*P*~adj~).

^*c*^ For adolescents in the follow-up group, improvement in CDRS-R positively correlated with improvement in SICI-4 (*P* = .01; *R*^2^ = 0.63).

Follow-up Assessment of Depressed Participants {#s10}
----------------------------------------------

Ten of the depressed participants who were treated with antidepressant medications returned for a follow-up visit about 8 weeks later (mean \[SD\] follow-up time, 7.9 \[5.6\] weeks; range, 2--20 weeks). Four continued to have clinically significant depressive symptoms based on their CDRS-R scores (scores remained ≥40). Mean (SD) changes in CDRS-R and CGI-S scores were −21.9 (9.26) and −2.2 (1.14), respectively.

We further tested the association between the change in CDRS-R scores (the difference between follow-up and baseline scores, ΔCDRS-R) and change in SICI-2 and SICI-4 (ΔSICI-2; ΔSICI-4) in robust regression models controlled for age and sex. Larger negative numbers for ΔCDRS-R indicated greater improvement in depressive symptoms, whereas larger negative numbers for ΔSICI-2 and ΔSICI-4 indicated greater improvement in cortical inhibition (ie, greater reduction of the conditioned/unconditioned MEP amplitude ratio). Improvement in CDRS-R positively correlated with improvement in ΔSICI-4 (*P* = .01; *R*^2^ = 0.63). There was no significant relationship with ΔSICI-2 (*P* = .10; *R*^2^ = 0.33) ([Figure 2](#F2){ref-type="fig"}). Given the variability in follow-up times among participants (2--20 weeks), we ran a secondary analysis looking at the relationship between ΔSICI and time elapsed between visits using additional regression models (not age and sex controlled). We found no association between follow-up time and either ΔSICI-2 or ΔSICI-4 (both *P* \> .05)

![Scatter plot graphs showing the association between change in Children's Depression Rating Scale, Revised (CDRS-R) (ΔCDRS-R) and change in short-interval intracortical inhibition (SICI)-2 (ΔSICI-2) and SICI-4 (ΔSICI-4). Greater improvement in CDRS-R (more negative difference) corresponded to greater improvement in cortical inhibition (more negative difference). DIFF, difference.](pyz021f0002){#F2}

Sensitivity Analyses {#s11}
--------------------

We performed an exploratory sensitivity analysis comparing baseline excitability measures between healthy and depressed groups, excluding participants on stimulants. Results of the robust regression analysis were similar and remained significant (SICI-2: *P* = .007; SICI-4: *P* = .051), suggesting that stimulant use did not account for the baseline differences between the groups. Of note, stimulants were held on the day of assessments with the goal of preventing the possible impact on cortical excitability measures. We also conducted a sensitivity analysis for patients who were treated with fluoxetine (excluding the patients who were on bupropion and escitalopram) to test the possible effects of different medications on cortical excitability. Robust regression analysis of the correlation between the change in CDRS-R scores (ΔCDRS-R) and change in cortical inhibition (ΔSICI-2 and ΔSICI-4), controlled for age and sex, showed similar results (SICI-2: *P* = .127; SICI-4: *P* \< .001) even when excluding the patients who were taking medications other than fluoxetine.

Discussion {#s12}
==========

To our knowledge, this is the first longitudinal study of TMS measures of cortical inhibition and excitability in adolescents with depression. Adolescents with moderate to severe symptoms of MDD had impaired cortical inhibition compared with healthy controls. Improvement in depressive symptom severity with antidepressant treatment was associated with restored cortical inhibition, as indexed by improved SICI.

Our results are consistent with prior TMS studies of adults that showed impaired SICI for patients with depressive disorders, further supporting the role of impaired GABA~A~-mediated cortical inhibition in depression ([@CIT0011]). In a meta-analysis ([@CIT0062]) of 3 studies (115 adult patients with MDD and 130 healthy controls), ([@CIT0006]; [@CIT0044]; [@CIT0045]) SICI was markedly impaired in the MDD group. Results of that meta-analysis also showed shortened CSP in MDD, suggesting impaired GABA~B~-mediated cortical inhibition. However, we did not find any significant differences in CSP in the current study. In contrast to adult studies, prior TMS studies with depressed adolescents have reported mixed results. Croarkin and colleagues ([@CIT0012]) previously found that medication-naïve children and adolescents with MDD had increased ICF compared with healthy controls, but no significant differences were observed for cortical inhibition measures, including SICI and CSP. However, in a separate posthoc analysis, depression severity negatively correlated with ICF and CSP, despite the absence of group differences ([@CIT0046]). In the current study, we did not find any difference in ICF or identify correlations between baseline depression severity and TMS measures. However, it is important to note that the group with depression in the aforementioned adolescent studies ([@CIT0012]; [@CIT0046]) differed from the sample in the current study with regard to previous antidepressant medication history, lower mean age (13.9 vs 15.4 years), shorter disease duration (0.9 vs 1.3 years), and exclusion of other comorbid psychiatric disorders (in the previous study).

Overall, the results of the current study suggest that older, previously treated adolescents with MDD and a longer duration of illness might have cortical excitability patterns that are similar to those of depressed adults, even though adolescents may not have adult levels of cortical maturation. An intermediate level of maturation in our sample of adolescents with depression could explain some of the differences between our results and those of previous adult studies (e.g., shortened CSP, a marker of GABA~B~-mediated cortical inhibition, which was not present in our depressed group) while supporting other similarities (e.g., impaired SICI). A known difference between adults and children is that children have less cortical inhibition ([@CIT0049]), which might have contributed to the lack of CSP findings in our sample. CSP also can show variability in children and adolescents ([@CIT0028]) and is affected by interhemispheric differences; these potential confounders were not assessed in this study. Moreover, different TMS indices may have differing patterns of age- or maturation-related changes along different time courses, and little is known about the developmental trajectories of TMS measures in the setting of psychiatric illness ([@CIT0014]). For example, prior work suggests that depressed children and adolescents might have delayed maturation of cortical excitability when compared with age-matched controls ([@CIT0014]). Additionally, several other psychiatric disorders in adults ([@CIT0062]), as well as attention-deficit/hyperactivity disorder in children ([@CIT0030]), have been associated with impaired excitatory-inhibitory balance. In contrast to previous adolescent studies, we did not exclude participants with comorbid psychiatric disorders; thus, the sample from our present study may be more generalizable to adolescents encountered in typical clinical settings.

The most notable finding of this study was the positive association between the improvement in depression severity and improvement in SICI after antidepressant therapy. Given that SICI indirectly reflects GABA~A~ activity ([@CIT0034]; [@CIT0020], [@CIT0022]; [@CIT0038]; [@CIT0035]), this result suggests that restored GABAergic inhibition is associated with improved depression severity in the setting of antidepressant treatment. Prior research in adults has shown restored GABAergic activity with therapeutic interventions such as electroconvulsive therapy ([@CIT0065]), repetitive TMS (rTMS) ([@CIT0016]), and selective serotonin reuptake inhibitors (SSRIs) ([@CIT0064]). Daskalakis and colleagues ([@CIT0016]) found state-dependent effects of rTMS on SICI in healthy participants and showed that those with less cortical inhibition at baseline (higher SICI ratios) showed more improvement in SICI after rTMS. They also showed potentiation of CSP with high- and low-frequency rTMS. In a proton magnetic resonance spectroscopy study of patients with MDD, Sanacora and colleagues ([@CIT0064]) showed that occipital GABA levels increased after treatment with SSRIs. Other studies also showed increased SICI (greater inhibition) in patients with MDD and healthy controls after administration of SSRIs ([@CIT0050]; [@CIT0063]). Even though no study has assessed longitudinal changes in TMS measures in adolescents, another study of depressed adolescents from our group has shown an association between pretreatment LICI impairment (which reflects GABA~B~-mediated activity) and poor treatment response to fluoxetine, suggesting that deficits in GABA~B~ functioning may be associated with treatment nonresponse ([@CIT0013]). In our study, almost all patients had some degree of improvement in their total CDRS-R scores (range, −3 to −38), which may explain the lack of differences in these GABA~B~ measures. It is possible that adolescent samples with greater degrees of treatment resistance would show different relationships between the change in depressive symptoms and changes in LICI and CSP.

Several mechanisms potentially explain how serotonergic (5-HT) activity and GABAergic activity interact. First, GABAergic neurons inhibit 5-HT neurons in midbrain raphe nuclei ([@CIT0071]). Also, previous research has shown that the serotonergic innervation of the cortex is mediated through the excitatory effects of 5-HT~2A~ and 5-HT~3~ receptors on GABAergic interneurons in the cortex, hippocampus, and amygdala ([@CIT0025]; [@CIT0040]). Indeed, 5-HT~2~ and 5-HT~3~ agonists increase the activity of GABAergic interneurons in these areas ([@CIT0029]; [@CIT0001]). These findings are consistent with aforementioned studies showing temporary increases in cortical inhibition, as measured by TMS, after administration of single doses of clomipramine ([@CIT0050]) and citalopram ([@CIT0063]). When administered regularly, SSRIs can induce plasticity within these neural networks ([@CIT0055]; [@CIT0048]). Although it is difficult to ascertain whether the modulation of GABAergic activity with SSRIs leads to improvement of depressive symptoms or whether improvement in depressive symptoms through other mechanisms leads to changes in inhibitory and excitatory networks, our results suggest that SICI is a potential treatment target in depression because of its potential to index deficits in GABAergic activity.

There are several limitations of this study. First, our sample size for the follow-up group was small and did not allow us to control for all potential covariates of interest. We also had a relatively heterogeneous group with regard to age, race/ethnicity, current medications, and history of prior antidepressant use. With regard to the potential impact of race or ethnicity, we are not aware of any previous studies comparing cortical excitability measures between black and white participant groups; however, one small study showed cortical excitability differences between Han Chinese and Caucasians ([@CIT0074]). On the other hand, comparisons of TMS measures, including our main findings (SICI-2, SICI-4), between black and white participants within the healthy group did not show any significant differences between these groups. In terms of medication use, our sensitivity analysis showed similar results when we excluded participants taking medications other than fluoxetine. Although the mean age of the healthy participants was lower than that of the depressed participants, we did control for age in the statistical analyses. Further, younger participants would be expected to have greater SICI-2 impairment ([@CIT0049]). Despite this age difference in our study, the older depressed sample had greater SICI-2 impairment. Finally, TMS testing of the motor cortex employed manual localization of the APB "hotspot." This could introduce bias into MEP findings based on the variability of pulses among subjects and between sessions, with potential resultant changes in cortical inhibition. While our methodology attempted to mitigate the potential bias that this could have introduced among MEP measures, future studies should utilize position tracking devices, conventional measurement (e.g., 10--20 EEG system), or neuro-navigation ([@CIT0002]). The major strength of our study was being the first study, to our knowledge, to compare longitudinal changes in TMS measures associated with adolescent depression before and after treatment. This study adds important preliminary data to the existing literature toward developing target biomarkers of depression and antidepressant treatment.

Conclusion {#s13}
==========

In this naturalistic, longitudinal study investigating TMS markers in adolescents with MDD, we showed that cortical inhibition was impaired, with patterns somewhat similar to those reported for adults with depression. Moreover, we showed that improvement in depression severity after antidepressant treatment is associated with restored cortical inhibition, as indexed by SICI. This was the first study to our knowledge to investigate longitudinal changes in TMS measures of cortical inhibition associated with antidepressant treatment in an adolescent population. These findings provide important preliminary data that will inform future studies investigating the neurobiology of adolescent depression and enable the development of better diagnostic methods and individualized, biomarker-guided therapeutic approaches in this population.
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